264 related articles for article (PubMed ID: 23253926)
1. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
[TBL] [Abstract][Full Text] [Related]
3. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
4. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort.
Kuster S; Jordan S; Elhai M; Held U; Steigmiller K; Bruni C; Cacciapaglia F; Vettori S; Siegert E; Rednic S; Codullo V; Airo P; Braun-Moscovici Y; Hunzelmann N; Joao Salvador M; Riccieri V; Gheorghiu AM; Alegre Sancho JJ; Romanowska-Prochnicka K; Castellví I; Kötter I; Truchetet ME; López-Longo FJ; Novikov PI; Giollo A; Shirai Y; Belloli L; Zanatta E; Hachulla E; Smith V; Denton C; Ionescu RM; Schmeiser T; Distler JHW; Gabrielli A; Hoffmann-Vold AM; Kuwana M; Allanore Y; Distler O;
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328401
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience.
Castellví I; Elhai M; Bruni C; Airò P; Jordan S; Beretta L; Codullo V; Montecucco CM; Bokarewa M; Iannonne F; Balbir A; Hsu VM; Distler O; Matucci-Cerinic M; Allanore Y;
Semin Arthritis Rheum; 2020 Dec; 50(6):1489-1493. PubMed ID: 32165035
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus.
Ikeda K; Sanayama Y; Makita S; Hosokawa J; Yamagata M; Nakagomi D; Takabayashi K; Nakajima H
Clin Dev Immunol; 2013; 2013():697525. PubMed ID: 24324510
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
Zacay G; Levy Y
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
[TBL] [Abstract][Full Text] [Related]
11. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique.
Distler JH; Jordan S; Airo P; Alegre-Sancho JJ; Allanore Y; Balbir Gurman A; Caporali R; Caramaschi P; Carreira PE; Chizzolini C; Cutolo M; Tuncay Duruöz M; Farge-Bancel D; Hesselstrand R; Iannone F; De Keyser F; Kucharz EJ; Launay D; García de la Peña Lefebvre P; Lukacova O; Marasini B; Martinovic D; Marques Neto JF; Radic M; Rednic S; Riemekasten G; Rovensky J; Seidel MF; Senel S; Smith V; Sunderkötter C; Ton E; van Laar JM; Matucci-Cerinic M; Müller Ladner U; Distler O
Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S40-5. PubMed ID: 21586217
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
Yazici Y; Curtis JR; Ince A; Baraf H; Malamet RL; Teng LL; Kavanaugh A
Ann Rheum Dis; 2012 Feb; 71(2):198-205. PubMed ID: 21949007
[TBL] [Abstract][Full Text] [Related]
14. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
Massarotti EM
Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
16. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis.
Omair MA; Phumethum V; Johnson SR
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S55-9. PubMed ID: 22691210
[TBL] [Abstract][Full Text] [Related]
18. Abatacept induces clinical improvement in patients with severe systemic sclerosis.
de Paoli FV; Nielsen BD; Rasmussen F; Deleuran B; Søndergaard K
Scand J Rheumatol; 2014; 43(4):342-5. PubMed ID: 25088011
[No Abstract] [Full Text] [Related]
19. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
Swierkot J; Madej M
Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
[TBL] [Abstract][Full Text] [Related]
20. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
